{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:37:01Z","timestamp":1770741421579,"version":"3.49.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.2217\/imt-2017-0143","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T08:48:44Z","timestamp":1535446124000},"page":"987-998","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Immunotherapy in Melanoma"],"prefix":"10.1080","volume":"10","author":[{"given":"Emily","family":"Feld","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara C","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pennsylvania, Philadelphia, PA19104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9656-2"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.04.005"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2015-0045"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"e_1_3_2_8_1","unstructured":"Coit DG ThompsonJA . NCCCN clinical practice guidelines in oncology (NCCN Guidelines): Melanoma . Version 1.2018\u2013October 11 ( 2017 )."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0500"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2370"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2006.01.011"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"e_1_3_2_14_1","volume-title":"American Society of Clinical Oncology (ASCO) 2017","author":"Tarhini AA","year":"2017","unstructured":"Tarhini AA , LeeSJ , HodiFSet al. A Phase III randomized study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms . Presented at : American Society of Clinical Oncology (ASCO) 2017 . Chicago, IL, USA , 2\u20136 June 2017 ."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.7"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1103-3"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.185"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61033-8"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.06.004"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000148"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_3_2_42_1","volume-title":"American Society of Clinical Oncology (ASCO) 2017","author":"Tawbi H","year":"2017","unstructured":"Tawbi H , ForsythPA , AlgaziAPet al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the Phase II study CheckMate 204 . Presented at : American Society of Clinical Oncology (ASCO) 2017 . Chicago, IL, USA , 2\u20136 June 2017 ."},{"key":"e_1_3_2_43_1","volume-title":"American Society of Clinical Oncology (ASCO) 2017","author":"Long GV","year":"2017","unstructured":"Long GV , AtkinsonV , MenzierAMet al. A randomized Phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the Anti-PD1 Brain Collaboration (ABC) . Presented at : American Society of Clinical Oncology (ASCO) 2017 . Chicago, IL, USA , 2\u20136 June 2017 ."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30428-X"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302338"},{"key":"e_1_3_2_46_1","volume-title":"American Society of Clinical Oncology (ASCO) 2017","author":"Ascierto PA","year":"2017","unstructured":"Ascierto PA , MeleroI , BhatiaSet al. Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy . Presented at : American Society of Clinical Oncology (ASCO) 2017 . Chicago, IL, USA , 2\u20136 June 2017 ."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1248402"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000186"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2008.0607"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.2477"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw181"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1418-6"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2017-0143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:19:23Z","timestamp":1715959163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2017-0143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.2217\/imt-2017-0143"],"URL":"https:\/\/doi.org\/10.2217\/imt-2017-0143","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}